mp.weixin.qq.com· Best in Class·· 10 hours agoPickScore77
INTerpath-001 Data Reportedly Leaked Ahead of ESMO 2026, Moderna Shares Plunge
In brief
Detailed INTerpath-001 data appear to have leaked ahead of ESMO 2026, raising efficacy questions and sending Moderna shares sharply lower. According to the original report, after a median follow-up of 24.6 months, adding intismeran to pembrolizumab reduced the risk of recurrence or death, HR = 0.58. At 2 years, 82.2% of patients on the combination were alive and recurrence-free versus 70.0% on pembrolizumab alone.
Why it matters
The brief lists INTerpath-001's HR and 2-year recurrence-free survival comparison, giving context for efficacy questions raised by the suspected leak.
Source: mp.weixin.qq.com · mp.weixin.qq.com